| Theme | NASH 2018 | |
|---|---|---|
| Title | The Actual Situation of Hepato-carcinogenesis in Nonalcoholic Steatohepatitis | |
| Publish Date | 2018/01 | |
| Author | Yoshito Itoh | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Kanji Yamaguchi | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Atsushi Umemura | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Michihisa Moriguchi | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Tasuku Hara | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| Author | Yuya Seko | Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine |
| [ Summary ] | Nonalcoholic fatty liver disease (NAFLD)‒hepatocellular carcinoma (HCC) is estimated to account for 2.0 % of the total HCC cases in Japan. The annual incidence of HCC in NAFLD after a health check‒up has been reported to be low, whereas its incidence in liver cirrhosis is around 2‒3 %. Non‒B non‒C HCC accounted for 10 % of the total HCC cases, which recently exceeded 20 %, presumably attributed to an increase in the incidence of obesity. Metabolic syndrome not only causes NAFLD / nonalcoholic steatohepatitis (NASH) but also may accelerate hepato‒carcinogenesis. HCC ranks at the top among the cancers associated with diabetes mellitus and its risk ratio is 2.5. Polymorphisms in PNPLA3 rs738409 are associated with hepatic steatosis as well as fibrosis with its risk allele G. A report from Europe, as well as our data, indicated that PNPLA3 rs738409 GG contributed not only to hepatic steatosis and fibro‒genesis but also to hepato‒carcinogenesis. | |